Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

NCT01814046 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

NIH

Sponsor class

Stopped Investigator left the National Institutes of Health (NIH)

Conditions

Metastatic Ocular Melanoma
Metastatic Uveal Melanoma

Interventions

DRUG: Aldesleukin
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Young Tumor Infiltrating Lymphocytes (TIL)

Sponsor

National Cancer Institute (NCI)